TOP TEN perturbations for 1553594_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553594_a_at
Selected probe(set): 214572_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553594_a_at (214572_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

endometriosis study 1 / normal ovary tissue

Relative Expression (log2-ratio):-3.3416576
Number of Samples:18 / 5
Experimental endometriosis study 1
Endometrium and ovary tissue from patients with endometriosis.
Control normal ovary tissue
Normal ovary tissue.

ovarian tumor study 28 (serous cystadenocarcinoma) / ovarian tumor study 28 (endometrioid carcinoma)

Relative Expression (log2-ratio):-2.2836533
Number of Samples:71 / 6
Experimental ovarian tumor study 28 (serous cystadenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma.
Control ovarian tumor study 28 (endometrioid carcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with endometrioid carcinoma.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (endometrioid carcinoma)

Relative Expression (log2-ratio):-2.2671118
Number of Samples:44 / 6
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (endometrioid carcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with endometrioid carcinoma.

expO ovary cancer study 1 (papillary serous cystadenocarcinoma, NOS; primary) / expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)

Relative Expression (log2-ratio):-2.256606
Number of Samples:66 / 2
Experimental expO ovary cancer study 1 (papillary serous cystadenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with papillary serous cystadenocarcinoma (NOS).
Control expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS).

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; primary) / expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)

Relative Expression (log2-ratio):-2.2529945
Number of Samples:15 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with serous cystadenocarcinoma (NOS).
Control expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS).

ovarian tumor study 28 (serous cystadenocarcinoma) / ovarian tumor study 28 (mucocarcinoid tumor)

Relative Expression (log2-ratio):-2.2482996
Number of Samples:71 / 7
Experimental ovarian tumor study 28 (serous cystadenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma.
Control ovarian tumor study 28 (mucocarcinoid tumor)
Primary tumor tissue sample obtained from the ovary of female patients with malignant mucocarcinoid tumor.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (mucocarcinoid tumor)

Relative Expression (log2-ratio):-2.231758
Number of Samples:44 / 7
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (mucocarcinoid tumor)
Primary tumor tissue sample obtained from the ovary of female patients with malignant mucocarcinoid tumor.

pediatric meningococcal sepsis study 1 (72h; blood) / normal blood sample

Relative Expression (log2-ratio):2.1973944
Number of Samples:2 / 3
Experimental pediatric meningococcal sepsis study 1 (72h; blood)
Blood samples collected from children with (suspected) meningococcal sepsis 72 hours after admission to the pediatric intensive care unit (PICU).
Control normal blood sample
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI.

expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary) / expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)

Relative Expression (log2-ratio):-2.196725
Number of Samples:12 / 2
Experimental expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with clear cell adenocarcinoma (NOS).
Control expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS).

expO ovary cancer study 1 (papillary serous cystadenocarcinoma, NOS; primary) / expO ovary cancer study 1 (mucinous adenocarcinoma; primary)

Relative Expression (log2-ratio):-2.0735292
Number of Samples:66 / 6
Experimental expO ovary cancer study 1 (papillary serous cystadenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with papillary serous cystadenocarcinoma (NOS).
Control expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.